Predictors of change in carotid atherosclerotic plaque inflammation and burden as measured by 18-FDG-PET and MRI, respectively, in the dal-PLAQUE study

International Journal of Cardiovascular Imaging

Volumn 30, Issue 3, 2014, Pages 571-582

  Mani, Venkatesh ^a   Woodward, Mark ^b   Samber, Daniel ^a   Bucerius, Jan ^a,c   Tawakol, Ahmed ^d   Kallend, David ^e   Rudd, James H F ^f   Abt, Markus ^e   Fayad, Zahi A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Fluorodeoxyglucose positron emission tomography; Inflammation; Magnetic resonance imaging; Plaque burden

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; PHOSPHOLIPASE A2; PLASMINOGEN ACTIVATOR INHIBITOR 1; DALCETRAPIB; FLUORODEOXYGLUCOSE F 18; HYPOCHOLESTEROLEMIC AGENT; RADIOPHARMACEUTICAL AGENT; THIOL DERIVATIVE;

ADULT; ARTICLE; CAREGIVER BURDEN; CAROTID ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VASCULITIS; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DIAGNOSTIC USE; MULTICENTER STUDY; PLAQUE, ATHEROSCLEROTIC; PREDICTIVE VALUE; PROCEDURES; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; CORONARY ARTERY DISEASE; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SULFHYDRYL COMPOUNDS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84899107540     PISSN: 15695794     EISSN: 15730743     Source Type: Journal    
DOI: 10.1007/s10554-014-0370-7     Document Type: Article

References (33)

1. Lobatto ME, Fuster V, Fayad ZA, Mulder WJ (2011) Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov 10:835-852
2. Underhill HR, Hatsukami TS, Fayad ZA, Fuster V, Yuan C (2010) MRI of carotid atherosclerosis: clinical implications and future directions. Nat Rev Cardiol 7:165-173
3. Sekikawa A, Curb JD, Edmundowicz D, Okamura T, Choo J, Fujiyoshi A, Masaki K, Miura K, Kuller LH, Shin C, Ueshima H (2012) Coronary artery calcification by computed tomography in epidemiologic research and cardiovascular disease prevention. J Epidemiol 22:188-198
4. Paraskevas KI, Wierzbicki AS, Mikhailidis DP (2012) Statins and noncardiac vascular disease. Curr Opin Cardiol 27:392-397
5. Fryburg DA, Vassileva MT (2011) Atherosclerosis drug development in jeopardy: the need for predictive biomarkers of treatment response. Sci Transl Med 3(72):1-5
6. Fayad ZA, Mani V, Woodward M, Kallend D, Bansilal S, Pozza J, Burgess T, Fuster V, Rudd JH, Tawakol A, Farkouh ME (2011) Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Am Heart J 162(2):214-221
7. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, Johnström P, Davenport AP, Kirkpatrick PJ, Arch BN, Pickard JD, Weissberg PL (2002) Imaging atherosclerotic plaque inflammation with [18F]- fluorodeoxyglucose positron emission tomography. Circulation 105:2708-2711 (Pubitemid 34615139)
8. James OG, Christensen JD, Wong TZ, Borges-Neto S, Koweek LM (2011) Utility of FDG PET/CT in inflammatory cardiovascular disease. Radiographics 31:1271-1286
9. Mizoguchi M, Tahara N, Tahara A, Nitta Y, Kodama N, Oba T, Mawatari K, Yasukawa H, Kaida H, Ishibashi M, Hayabuchi N, Harada H, Ikeda H, Yamagishi S, Imaizumi T (2011) Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging 4:1110-1118
10. Ogawa M, Nakamura S, Saito Y, Kosugi M, Magata Y (2012) What can be seen by 18F-FDG PET in atherosclerosis imaging? The effect of foam cell formation on 18F-FDG uptake to macrophages in vitro. J Nucl Med 53:55-58
11. Rosenbaum D, Millon A, Fayad ZA (2012) Molecular imaging in atherosclerosis: FDG PET. Curr Atheroscler Rep 14:429-437
12. Tardif JC, Lesage F, Harel F, Romeo P, Pressacco J (2011) Imaging biomarkers in atherosclerosis trials. Circ Cardiovasc Imaging 4:319-333
13. Corti R, Fuster V (2011) Imaging of atherosclerosis: magnetic resonance imaging. Eur Heart J 32(14):1709-1719
14. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardif JC, Rudd JH, Farkouh ME, Tawakol A, dal-PLAQUE Investigators (2011) Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 378:1547-1559
15. Fayad ZA, Mani V, Fuster V (2012) The time has come for clinical cardiovascular trials with plaque characterization as an endpoint. Eur Heart J 33:160-161
16. Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, Rafique A, Hargeaves R, Farkouh M, Fuster V, Fayad ZA (2008) Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med 49:871-878 (Pubitemid 351793426)
17. El Aidi H, Mani V, Weinshelbaum KB, Aguiar SH, Taniguchi H, Postley JE, Samber DD, Cohen EI, Stern J, van der Geest RJ, Reiber JH, Woodward M, Fuster V, Gidding SS, Fayad ZA (2009) Cross-sectional, prospective study of MRI reproducibility in the assessment of plaque burden of the carotid arteries and aorta. Nat Clin Pract Cardiovasc Med 6:219-228
18. Investigators AIM-HIGH, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365:2255-2267
19. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849-1861
20. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, dal-OUTCOMES Investigators (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089-2099
21. Hayashi K, Mani V, Nemade A, Aguiar S, Postley JE, Fuster V, Fayad ZA (2010) Variations in atherosclerosis and remodeling patterns in aorta and carotids. J Cardiovasc Magn Reson 12:10
22. Mani V, Muntner P, Gidding SS, Aguiar SH, El Aidi H, Weinshelbaum KB, Taniguchi H, van der Geest R, Reiber JH, Bansilal S, Farkouh M, Fuster V, Postley JE, Woodward M, Fayad ZA (2009) Cardiovascular magnetic resonance parameters of atherosclerotic plaque burden improve discrimination of prior major adverse cardiovascular events. J Cardiovasc Magn Reson 11:10
23. Bucerius J, Duivenvoorden R, Mani V, Moncrieff C, Rudd JH, Calcagno C, Machac J, Fuster V, Farkouh ME, Fayad ZA (2011) Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study. JACC Cardiovasc Imaging 4:1195-1205
24. Hashizume M, Mihara M (2012) Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors. Cytokine 58:424-430
25. Reimers GJ, Jackson CL, Rickards J, Chan PY, Cohn JS, Rye KA, Barter PJ, Rodgers KJ (2011) Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-I. Cardiovasc Res 91:37-44
26. Morgantini C, Imaizumi S, Grijalva V, Navab M, Fogelman AM, Reddy ST (2010) Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes. Diabetes 59:3223-3228
27. Cimmino G, Ibanez B, Vilahur G, Speidl WS, Fuster V, Badimon L, Badimon JJ (2009) Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-I(Milano). J Cell Mol Med 13:3226-3235
28. Hu MM, Zhang J, Wang WY, Wu WY, Ma YL, Chen WH, Wang YP (2011) The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice. Acta Pharmacol Sin 32:1253-1258
29. Gonçalves I, Edsfeldt A, Ko NY, Grufman H, Berg K, Björkbacka H, Nitulescu M, Persson A, Nilsson M, Prehn C, Adamski J, Nilsson J (2012) Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation. Arterioscler Thromb Vasc Biol 32:1505-1512
30. Agirbasli M (2005) Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract 59:102-106
31. Raiko JR, Oikonen M, Wendelin-Saarenhovi M, Siitonen N, Kähönen M, Lehtimäki T, Viikari J, Jula A, Loo BM, Huupponen R, Saarikoski L, Juonala M, Raitakari OT (2012) Plasminogen activator inhitor-1 associates with cardiovascular risk factors in healthy young adults in the Cardiovascular Risk in Young Finns Study. Atherosclerosis 224:208-212
32. Mani V, Aguiar SH, Itskovich VV, Weinshelbaum KB, Postley JE, Wasenda EJ, Aguinaldo JG, Samber DD, Fayad ZA (2006) Carotid black blood MRI burden of atherosclerotic disease assessment correlates with ultrasound intima-media thickness. J Cardiovasc Magn Reson 8:529-534
33. Bucerius J, Mani V, Moncrieff C, Rudd JH, Machac J, Fuster V, Farkouh ME, Fayad ZA (2012) Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol 59:2080-2088